New concepts in post-infarction vetricular remodeling

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 3, 2003, Pages

  Udelson, James E ^a   Patten, Richard D ^a   Konstam, Marvin A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blocker; Angiotensin converting enzyme inhibitor; Left ventricular remodeling; Myocardial infarction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO;

ARTICLE; DISEASE COURSE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HUMAN; LONG TERM CARE; MORTALITY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; TISSUE REGENERATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0141505923     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Patten RD, Udelson JE, Konstam MA. Ventricular remodeling and its prevention in the treatment of heart failure. Curr Opin Cardiol. 1998;13:162-167.
2. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction, experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
3. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72:406-412.
4. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res. 1993;73:413-423.
5. Taylor K, Patten RD, Smith JJ, et al. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol. 1998;31:654-660.
6. Mulrow PJ. Angiotensin II and aldosterone regulation. Regul Pept. 1999;80:27-32.
7. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
8. Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-2701.
9. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000; 101:558-569.
10. Spyrou N, Rosen SD, Fath-Ordoubadi F, et al. Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol. 2000;36:2072-2080.
11. Mann DL. Stress activated cytokines and the heart. Cytokine Growth Factor Rev. 1996; 7:341-354.
12. Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95:1247-1252.
13. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865.
14. Dodge HT, Sandler H, Ballew DW, et al. Use of biplane angiocardiography for the measurement of left ventricular volume in man. Am Heart J. 1960;60:762.
15. Konstam MA, Wynne J, Holman BL, et al. Use of equilibrium (gated) radionuclide ventriculography to quantitate left ventricular output in patients with and without left-sided valvular regurgitation. Circulation. 1981;64:578-585.
16. Schiller NB. Two-dimensional echocardiographic determination of left ventricular volume, systolic function and mass. Circulation. 1991;84:280-287.
17. Migrino RQ, Young JB, Ellis SG, et al for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. Circulation. 1997;96:116-121.
18. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76: 44-51.
19. Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993;72:672-676.
20. Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol. 1989;14:564-570.
21. Pfeffer MA, Braunwald E, Moye LA, et al for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
22. Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80-86.
23. St. John Sutton M, Pfeffer MA, Plappert T, et al for the SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction, the protective effect of captopril. Circulation. 1994;89:68-75.
24. Gaudron P, Kugler I, Hu K, et al. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their inter-relation and prognostic impact. J Am Coll Cardiol. 2001;38:33-40.
25. The SOLVD, Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293-302.
26. Konstam MA, Rosseau MD, Kronenberg MW, et al for the SOLVD Investigators. Effects of the angiotensin-converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation. 1992;86:431-438.
27. Konstam MA, Kronenberg MW, Rousseau MF, et al for the SOLVD Investigators. Effects of the angiotensin-converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation. 1993;88:2277-2283.
28. Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation. 1997;96:183-191.
29. Doughty RN, Whalley GA, Walsh H, et al. Effects of carvedilol on left ventricular remodeling in patients following acute myocardial infarction: the CAPRICORN echo substudy [abstract]. Circulation. 2001;104:517.
30. Darghie HL. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
31. Wei S, Chow LTC, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol. 2000;36:276-281.
32. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1997;29:1060-1066.
33. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
34. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
35. Groenning B, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-2080.
36. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994;73:488-493.
37. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971-977.
38. Antonopoulos GV, Lau J, Konstam MA, Udelson JE: Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? Circulation. 1999;100:I-296.
39. St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577-2582.
40. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102:611-616.
41. Bozkurt BMD, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-1047.